Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells

Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells

Despite liver cancer being the second-leading cause of cancer-related death worldwide, few systemic drugs have been approved. Sorafenib, the first FDA-approved systemic drug for unresectable hepatocellular carcinoma (HCC), is limited by resistance. However, the precise mechanisms underlying this phe...

Full description

Bibliographic Details
Main Authors: Yeonghoon Son, Na-Rae Shin, Sung-Ho Kim, Su-Cheol Park, Hae-June Lee
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:International Journal of Molecular Sciences
Subjects:
hepatocellular carcinoma
fibrinogen-like protein 1
sorafenib
resistance
Online Access:https://www.mdpi.com/1422-0067/22/10/5330

Similar Items

Similar Items